Medical Oncology A.O. S. Croce e Carle Ospedale di Insegnamento, Cuneo, Italy.
Future Oncol. 2017 Dec;13(30):2759-2769. doi: 10.2217/fon-2017-0283. Epub 2017 Sep 13.
Eribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.
艾立布林是一种海鞘素 B 的人工合成类似物，属于微管靶向药物，具有独特的微管动力学抑制机制。该分子对肿瘤生物学具有多种非有丝分裂作用，对上皮-间充质转化和肿瘤血管生成具有作用。本文综述了艾立布林的临床前和临床研究。有丝分裂和非有丝分裂作用及其良好的安全性使艾立布林成为一种具有高度治疗转移性乳腺癌潜力的独特药物。艾立布林作用机制对血管重塑、微环境修饰和上皮-间充质转化逆转的新重视，为从免疫学角度重新思考该药物的应用铺平了道路。
